Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

140 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study.
Barthel H, Gertz HJ, Dresel S, Peters O, Bartenstein P, Buerger K, Hiemeyer F, Wittemer-Rump SM, Seibyl J, Reininger C, Sabri O; Florbetaben Study Group. Barthel H, et al. Among authors: gertz hj. Lancet Neurol. 2011 May;10(5):424-35. doi: 10.1016/S1474-4422(11)70077-1. Epub 2011 Apr 8. Lancet Neurol. 2011. PMID: 21481640 Clinical Trial.
Individualized quantification of brain β-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer's disease and healthy controls.
Barthel H, Luthardt J, Becker G, Patt M, Hammerstein E, Hartwig K, Eggers B, Sattler B, Schildan A, Hesse S, Meyer PM, Wolf H, Zimmermann T, Reischl J, Rohde B, Gertz HJ, Reininger C, Sabri O. Barthel H, et al. Among authors: gertz hj. Eur J Nucl Med Mol Imaging. 2011 Sep;38(9):1702-14. doi: 10.1007/s00259-011-1821-1. Epub 2011 May 6. Eur J Nucl Med Mol Imaging. 2011. PMID: 21547601 Clinical Trial.
Evaluation of software tools for automated identification of neuroanatomical structures in quantitative β-amyloid PET imaging to diagnose Alzheimer's disease.
Tuszynski T, Rullmann M, Luthardt J, Butzke D, Tiepolt S, Gertz HJ, Hesse S, Seese A, Lobsien D, Sabri O, Barthel H. Tuszynski T, et al. Among authors: gertz hj. Eur J Nucl Med Mol Imaging. 2016 Jun;43(6):1077-87. doi: 10.1007/s00259-015-3300-6. Epub 2016 Jan 7. Eur J Nucl Med Mol Imaging. 2016. PMID: 26739328
Feasibility and acceptance of simultaneous amyloid PET/MRI.
Schütz L, Lobsien D, Fritzsch D, Tiepolt S, Werner P, Schroeter ML, Berrouschot J, Saur D, Hesse S, Jochimsen T, Rullmann M, Sattler B, Patt M, Gertz HJ, Villringer A, Claßen J, Hoffmann KT, Sabri O, Barthel H. Schütz L, et al. Among authors: gertz hj. Eur J Nucl Med Mol Imaging. 2016 Nov;43(12):2236-2243. doi: 10.1007/s00259-016-3462-x. Epub 2016 Jul 19. Eur J Nucl Med Mol Imaging. 2016. PMID: 27435367
Histopathology and Florbetaben PET in Patients Incorrectly Diagnosed with Alzheimer's Disease.
Sabbagh MN, Schäuble B, Anand K, Richards D, Murayama S, Akatsu H, Takao M, Rowe CC, Masters CL, Barthel H, Gertz HJ, Peters O, Rasgon N, Jovalekic A, Sabri O, Schulz-Schaeffer WJ, Seibyl J. Sabbagh MN, et al. Among authors: gertz hj. J Alzheimers Dis. 2017;56(2):441-446. doi: 10.3233/JAD-160821. J Alzheimers Dis. 2017. PMID: 27983552 Clinical Trial.
140 results